Over the last year, the COVID-19 pandemic has placed healthcare for respiratory medicine firmly in the global spotlight. But even before this, over half a …
AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …
Owlstone Medical Ltd, a diagnostics company developing a breathalyzer for disease, today announced that GSK, a world leader in respiratory, will incorporate Owlstone Medical’s Breath …
GlaxoSmithKline’s (GSK) study showed that Anoro Ellipta is more effective than Stiolto Respimat in improving lung function in patients with chronic obstructive pulmonary disease (COPD). …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
